Suppr超能文献

在两次风暴之间,血管活性肽或缓激肽是 COVID-19 严重程度的基础?

Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?

机构信息

Department of Pharmaceutical Sciences and Center for Blood Brain Barrier Research, School of Pharmacy, TTUHSC, Amarillo, TX, USA.

出版信息

Physiol Rep. 2021 Mar;9(5):e14796. doi: 10.14814/phy2.14796.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to be a world-wide pandemic with overwhelming socioeconomic impact. Since inflammation is one of the major causes of COVID-19 complications, the associated molecular mechanisms have been the focus of many studies to better understand this disease and develop improved treatments for patients contracting SARS-CoV-2. Among these, strong emphasis has been placed on pro-inflammatory cytokines, associating severity of COVID-19 with so-called "cytokine storm." More recently, peptide bradykinin, its dysregulated signaling or "bradykinin storm," has emerged as a primary mechanism to explain COVID-19-related complications. Unfortunately, this important development may not fully capture the main molecular players that underlie the disease severity. To this end, in this focused review, several lines of evidence are provided to suggest that in addition to bradykinin, two closely related vasoactive peptides, substance P and neurotensin, are also likely to drive microvascular permeability and inflammation, and be responsible for development of COVID-19 pathology. Furthermore, based on published experimental observations, it is postulated that in addition to ACE and neprilysin, peptidase neurolysin (Nln) is also likely to contribute to accumulation of bradykinin, substance P and neurotensin, and progression of the disease. In conclusion, it is proposed that "vasoactive peptide storm" may underlie severity of COVID-19 and that simultaneous inhibition of all three peptidergic systems could be therapeutically more advantageous rather than modulation of any single mechanism alone.

摘要

新型冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的,目前仍在全球范围内流行,对社会经济造成了巨大影响。由于炎症是 COVID-19 并发症的主要原因之一,因此相关的分子机制一直是许多研究的重点,以更好地了解这种疾病并为感染 SARS-CoV-2 的患者开发更好的治疗方法。在这些研究中,人们强烈关注促炎细胞因子,将 COVID-19 的严重程度与所谓的“细胞因子风暴”联系起来。最近,肽缓激肽、其失调的信号转导或“缓激肽风暴”已成为解释 COVID-19 相关并发症的主要机制。不幸的是,这一重要发现可能并未完全捕捉到导致疾病严重程度的主要分子机制。为此,在本专题综述中,提供了一些证据表明,除了缓激肽外,两种密切相关的血管活性肽,即 P 物质和神经降压素,也可能导致微血管通透性增加和炎症,并导致 COVID-19 病理的发生。此外,基于已发表的实验观察结果,推测除 ACE 和 Neprilysin 外,肽酶神经肽酶(Nln)也可能有助于缓激肽、P 物质和神经降压素的积累,并促进疾病的发展。总之,提出“血管活性肽风暴”可能是 COVID-19 严重程度的基础,同时抑制这三种肽能系统可能比单独调节任何单一机制更具治疗优势。

相似文献

1
Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?
Physiol Rep. 2021 Mar;9(5):e14796. doi: 10.14814/phy2.14796.
7
Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Mar;395(3):275-283. doi: 10.1007/s00210-022-02206-6. Epub 2022 Jan 28.
8
Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.
Arch Med Res. 2021 Nov;52(8):777-787. doi: 10.1016/j.arcmed.2021.05.007. Epub 2021 Jun 5.
9
Structural basis of divergent substrate recognition and inhibition of human neurolysin.
Sci Rep. 2024 Aug 8;14(1):18420. doi: 10.1038/s41598-024-67639-w.
10
Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Front Immunol. 2021 Nov 11;12:749291. doi: 10.3389/fimmu.2021.749291. eCollection 2021.

引用本文的文献

1
Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review.
Viruses. 2024 Mar 15;16(3):455. doi: 10.3390/v16030455.
3
Impact of COVID-19 pneumonia on pulmonary vascular volume.
Front Med (Lausanne). 2023 Mar 22;10:1117151. doi: 10.3389/fmed.2023.1117151. eCollection 2023.
4
The role of Substance P in the defense line of the respiratory tract and neurological manifestations post COVID-19 infection.
Front Neurol. 2023 Mar 6;14:1052811. doi: 10.3389/fneur.2023.1052811. eCollection 2023.
5
The des-Arg-bradykinin/B1R axis: Hepatic damage in COVID-19.
Front Physiol. 2022 Dec 19;13:1080837. doi: 10.3389/fphys.2022.1080837. eCollection 2022.
7
Pathophysiology of Post-COVID syndromes: a new perspective.
Virol J. 2022 Oct 9;19(1):158. doi: 10.1186/s12985-022-01891-2.
8
Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations.
Front Cell Neurosci. 2022 Sep 16;16:977039. doi: 10.3389/fncel.2022.977039. eCollection 2022.
9
Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development.
Front Pharmacol. 2022 Aug 9;13:955648. doi: 10.3389/fphar.2022.955648. eCollection 2022.
10
Acute acalculous cholecystitis as an early manifestation of COVID-19: case report and literature review.
Acta Biomed. 2022 Jun 29;93(S1):e2022207. doi: 10.23750/abm.v93iS1.12760.

本文引用的文献

4
Methylene blue may have a role in the treatment of COVID-19.
Med Hypotheses. 2020 Nov;144:110163. doi: 10.1016/j.mehy.2020.110163. Epub 2020 Aug 6.
5
COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis.
Drug Des Devel Ther. 2020 Nov 19;14:5097-5108. doi: 10.2147/DDDT.S281700. eCollection 2020.
7
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.
Hypertension. 2020 Nov;76(5):1350-1367. doi: 10.1161/HYPERTENSIONAHA.120.15948. Epub 2020 Sep 28.
8
The role of peptidase neurolysin in neuroprotection and neural repair after stroke.
Neural Regen Res. 2021 Jan;16(1):21-25. doi: 10.4103/1673-5374.284904.
9
Natural α,β-unsaturated lactones inhibit neuropeptide-induced mast cell activation in an in vitro model of neurogenic inflammation.
Inflamm Res. 2020 Oct;69(10):1039-1051. doi: 10.1007/s00011-020-01380-8. Epub 2020 Jul 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验